RIKEN Research Center for Allergy and Immunology

Home > Laboratories > Cellular Immunotherapy
Cellular Immunotherapy
◆◆ WELCOME TO CELLULAR IMMUNOTHERAPY RESEARCH UNIT◆◆ 

O
ur group deals with tumor immunology, focusing on the link between innate and adaptive 

immunities through the interaction between dendritic cells (DCs)and NKT cells. In addition to

the direct anti-tumor response of activated NKT cells, we found an adjuvant effect of alfa-galacto-

sylceramide (alfa-GalCer) in mice upon intravenous administration of antigen plus alfa-GalCer.

We are studying the process of activation of adaptive immunity, i.e. the mechanism of antitumor 
 
T cellimmunity mediated by augmented innate immunity, and have conducted investigations of 

adequate tumor antigen delivery systems. 

Our goal is to develop novel therapies for cancers employing a strategy to establish adaptive

antitumor immunity. Since it is often difficult to evaluate NKT cell function in patients with
 malignancies due to the reduced numbers of NKT cells, we have attempted to develop
 an approach to evaluate the functions of NKT cells and antigen presenting cells (APCs)
 in cancer patients to
understand the pathologic status of cancer disease.

 
Please feel free to contact us at the following.

◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇  
RIKEN Yokohama Institute
Research Center for Allergy and Immunology
Research Unit for Cellular Immunotherapy 

PHONE:+81-45-503-7063
FAX:+81-45-503-7061
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, 
Kanagawa,230-0045, Japan 
◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇◆◇